| 产品名称： | NCI-H526 H526 |
|---|---|
| 商品货号： | TS211260 |
| Organism： | Homo sapiens, human |
| Tissue： | lung; Derived from metastatic site: bone marrow |
| Cell Type： | epithelial |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | round clusters in suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | stage E,carcinoma; variant small cell lung cancer |
| Age： | 55 years adult |
| Gender： | male |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： |  |
| Derivation： | This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a bone marrow metastasis taken from a patient prior to therapy. |
| Clinical Data： | 55 years adult
Caucasian
male
|
| Receptor Expression： | insulin-like growth factor II (IGF II); bombesin |
| Oncogene： | myc +; myb +; fes +; fms +; raf +; ras + |
| Tumorigenic： | Yes |
| Effects： | Yes, the cells produce tumors in athymic nude mice |
| Comments： | NCI-H526 expresses elevated levels of 2 biochemical markers of SCLC: neuron specific enolase and the brain isoenzyme of creatine kinase.
They do not express L-dopa carboxylase or bombesin-like immunoreactivity.
These cells express the c-kit gene as well as the N-myc gene, but not c-myc or L-myc.
N-myc is amplified and p75 c-myb expression was observed.
NCI-H526 also expresses the proto-oncogenes N-ras, Ki-ras, Ha-ras, and c-raf1.
Only trace amounts of the retinoblastoma susceptibility gene, RB mRNA were detected.
RB protein was not detected.
The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.
Abnormally sized mRNA was present.
The line has a reported colony-forming efficiency of 4.2% in soft agarose. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases. Medium Renewal: Every 2 to 3 days xa0 |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11 D13S317: 13 D16S539: 9 D5S818: 11 D7S820: 9,12 THO1: 6,8 TPOX: 8,11 vWA: 16,17 |
| Population Doubling Time： | 36 hrs |
| Name of Depositor： | AF Gazdar, JD Minna |
| Deposited As： | Homo sapiens |
| References： | Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 Bepler G, et al. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50, 1989. PubMed: 2536917 Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141 Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Kiefer PE, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res. 47: 6236-6242, 1987. PubMed: 2824028 Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389 Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933 Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893 Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043 Bepler G, et al. Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 9: 1367-1372, 1988. PubMed: 2470067 NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. Lung Cancer 4: 155-161, 1988. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | NCI-H526 H526 |
|---|---|
| 商品货号： | TS211260 |
| Organism： | Homo sapiens, human |
| Tissue： | lung; Derived from metastatic site: bone marrow |
| Cell Type： | epithelial |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | round clusters in suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | stage E,carcinoma; variant small cell lung cancer |
| Age： | 55 years adult |
| Gender： | male |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： | |
| Derivation： | This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a bone marrow metastasis taken from a patient prior to therapy. |
| Clinical Data： | 55 years adult
Caucasian
male
|
| Receptor Expression： | insulin-like growth factor II (IGF II); bombesin |
| Oncogene： | myc +; myb +; fes +; fms +; raf +; ras + |
| Tumorigenic： | Yes |
| Effects： | Yes, the cells produce tumors in athymic nude mice |
| Comments： | NCI-H526 expresses elevated levels of 2 biochemical markers of SCLC: neuron specific enolase and the brain isoenzyme of creatine kinase.
They do not express L-dopa carboxylase or bombesin-like immunoreactivity.
These cells express the c-kit gene as well as the N-myc gene, but not c-myc or L-myc.
N-myc is amplified and p75 c-myb expression was observed.
NCI-H526 also expresses the proto-oncogenes N-ras, Ki-ras, Ha-ras, and c-raf1.
Only trace amounts of the retinoblastoma susceptibility gene, RB mRNA were detected.
RB protein was not detected.
The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.
Abnormally sized mRNA was present.
The line has a reported colony-forming efficiency of 4.2% in soft agarose. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases. Medium Renewal: Every 2 to 3 days xa0 |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 11 D13S317: 13 D16S539: 9 D5S818: 11 D7S820: 9,12 THO1: 6,8 TPOX: 8,11 vWA: 16,17 |
| Population Doubling Time： | 36 hrs |
| Name of Depositor： | AF Gazdar, JD Minna |
| Deposited As： | Homo sapiens |
| References： | Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 Bepler G, et al. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50, 1989. PubMed: 2536917 Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141 Lai SL, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 15: 225-232, 1995. PubMed: 7762988 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Kiefer PE, et al. Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res. 47: 6236-6242, 1987. PubMed: 2824028 Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389 Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933 Verbeeck MA, et al. Expression of the vasopressin and gastrin-releasing peptide genes in small cell lung carcinoma cell lines. Pathobiology 60: 136-142, 1992. PubMed: 1320893 Johnson BE, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J. Natl. Cancer Inst. 81: 1223-1228, 1989. PubMed: 2569043 Bepler G, et al. Substance P analogues function as bombesin receptor antagonists and inhibit small cell lung cancer clonal growth. Peptides 9: 1367-1372, 1988. PubMed: 2470067 NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. Lung Cancer 4: 155-161, 1988. |
